NASDAQ:GTHX
G1 Therapeutics Inc Stock News
$4.27
-0.220 (-4.90%)
At Close: May 06, 2024
G1 Therapeutics Announces Closing of Offering of Common Stock
09:01pm, Tuesday, 22'nd Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the closing of an underwritten public offer
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
10:58am, Monday, 21'st Nov 2022 Benzinga
Gainers
AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday.
FOXO Technologies Inc. (NYSE: FOXO) shares surged 46.9% to close at $0.6520 on Friday. Foxo Technologies re
Nasdaq Down 0.5%; Clearfield Shares Spike Higher
07:46pm, Friday, 18'th Nov 2022 Benzinga
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping over 50 points on Friday.
The Dow traded up 0.19% to 33,608.80 while the NASDAQ fell 0.50% to 11,089.07. The S&P
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
06:15pm, Friday, 18'th Nov 2022 Benzinga
Gainers
PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital.
Satixfy Communications Ltd. (N
Nasdaq Turns Lower; Crude Oil Down Over 3%
05:00pm, Friday, 18'th Nov 2022 Benzinga
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Friday.
The Dow traded up 0.42% to 33,686.06 while the NASDAQ fell 0.25% to 11,117.35. The S&P 500 also rose
Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday
04:01pm, Friday, 18'th Nov 2022 Benzinga
U.S. stocks traded mixed, with the Dow Jones gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.
G1 Therapeutics, Inc. (NASDAQ: GTHX) dipped 24% to $
Why Farfetch Shares Are Trading Lower; Here Are 26 Stocks Moving Premarket
12:43pm, Friday, 18'th Nov 2022 Benzinga
Gainers
PaxMedica, Inc. (NASDAQ: PXMD) shares rose 58.1% to $2.45 in pre-market trading. PaxMedica entered into committed equity investment agreement for up to $20 million with Lincoln Park Capital.
G1 Therapeutics Announces Pricing of Offering of Common Stock
01:12am, Friday, 18'th Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the pricing of an underwritten public offer
G1 Therapeutics Announces Proposed Public Offering of Common Stock
09:01pm, Thursday, 17'th Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it has commenced an underwritten publi
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
09:40am, Thursday, 03'rd Nov 2022 Benzinga
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Benefitfocus, Inc. (NASDAQ: BNFT) shares surged 48.2% to settle at $10.36 on We
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
05:28pm, Wednesday, 02'nd Nov 2022 Benzinga
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
Benefitfocus, Inc. (NASDAQ: BNFT) shares jumped 47.8% to $10.33 after the company announced it will
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
10:30am, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) -
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
10:28am, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy - - Data Suggest On-Target Effect of
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates
09:02am, Wednesday, 02'nd Nov 2022
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:40pm, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
